David Johnson Einstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 9 | 2023 | 10879 | 0.960 |
Why?
|
Terminal Care | 5 | 2017 | 1649 | 0.750 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 135 | 0.700 |
Why?
|
Receptors, Androgen | 3 | 2023 | 1035 | 0.700 |
Why?
|
Androstenes | 2 | 2019 | 169 | 0.690 |
Why?
|
Phenylurea Compounds | 1 | 2022 | 528 | 0.680 |
Why?
|
Compassionate Use Trials | 1 | 2018 | 46 | 0.670 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 111 | 0.660 |
Why?
|
Quinolines | 1 | 2022 | 723 | 0.610 |
Why?
|
Paternalism | 1 | 2016 | 45 | 0.580 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2021 | 750 | 0.560 |
Why?
|
Death | 2 | 2017 | 642 | 0.540 |
Why?
|
Telephone | 1 | 2019 | 613 | 0.540 |
Why?
|
Advance Directives | 1 | 2016 | 240 | 0.490 |
Why?
|
Empathy | 1 | 2018 | 458 | 0.480 |
Why?
|
Personal Autonomy | 1 | 2016 | 296 | 0.470 |
Why?
|
Physician-Patient Relations | 5 | 2022 | 3225 | 0.470 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4119 | 0.460 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3022 | 0.460 |
Why?
|
Cisplatin | 1 | 2019 | 1622 | 0.450 |
Why?
|
Facial Paralysis | 1 | 2015 | 296 | 0.420 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3478 | 0.380 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2021 | 2115 | 0.370 |
Why?
|
Sarcoidosis | 1 | 2015 | 496 | 0.370 |
Why?
|
Quality of Life | 2 | 2023 | 12113 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 8896 | 0.350 |
Why?
|
Immunotherapy | 4 | 2021 | 4257 | 0.340 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4309 | 0.330 |
Why?
|
Internal Medicine | 1 | 2015 | 1007 | 0.320 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 936 | 0.310 |
Why?
|
Neoplasms | 6 | 2022 | 20947 | 0.310 |
Why?
|
Internet | 1 | 2019 | 3018 | 0.290 |
Why?
|
Palliative Care | 2 | 2021 | 3359 | 0.280 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5169 | 0.270 |
Why?
|
Medical Oncology | 1 | 2017 | 2162 | 0.270 |
Why?
|
Decision Making | 2 | 2016 | 3837 | 0.250 |
Why?
|
Prostatectomy | 3 | 2023 | 1843 | 0.250 |
Why?
|
Radium | 1 | 2023 | 54 | 0.220 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13563 | 0.220 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 42 | 0.210 |
Why?
|
Thiohydantoins | 1 | 2021 | 20 | 0.200 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 190 | 0.200 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3837 | 0.200 |
Why?
|
Leuprolide | 1 | 2021 | 312 | 0.170 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3335 | 0.170 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 659 | 0.170 |
Why?
|
Humans | 31 | 2023 | 725001 | 0.170 |
Why?
|
Neutropenia | 1 | 2023 | 879 | 0.160 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 308 | 0.160 |
Why?
|
Nitriles | 2 | 2019 | 938 | 0.160 |
Why?
|
Morbidity | 1 | 2023 | 1729 | 0.150 |
Why?
|
Benzamides | 2 | 2019 | 1372 | 0.150 |
Why?
|
Urothelium | 1 | 2019 | 278 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1092 | 0.140 |
Why?
|
Prednisone | 1 | 2021 | 1551 | 0.140 |
Why?
|
Male | 17 | 2023 | 346964 | 0.140 |
Why?
|
Drug Approval | 1 | 2022 | 734 | 0.140 |
Why?
|
Erythema Nodosum | 1 | 2015 | 29 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1028 | 0.130 |
Why?
|
Internship and Residency | 1 | 2015 | 5690 | 0.130 |
Why?
|
Serine | 1 | 2018 | 822 | 0.130 |
Why?
|
Phylogeny | 1 | 2021 | 2789 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1356 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 785 | 0.110 |
Why?
|
Anecdotes as Topic | 1 | 2012 | 57 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1512 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2030 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1326 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1888 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 898 | 0.100 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3601 | 0.100 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 729 | 0.100 |
Why?
|
Hospice Care | 1 | 2017 | 627 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3575 | 0.090 |
Why?
|
Prognosis | 3 | 2020 | 28718 | 0.090 |
Why?
|
Biopsy | 1 | 2021 | 6725 | 0.090 |
Why?
|
Survival Analysis | 2 | 2020 | 10244 | 0.090 |
Why?
|
Virus Diseases | 1 | 2015 | 703 | 0.090 |
Why?
|
Culture | 1 | 2012 | 627 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2759 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8453 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2647 | 0.070 |
Why?
|
Risk Assessment | 4 | 2021 | 23178 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 14951 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 24043 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2019 | 10926 | 0.060 |
Why?
|
Phenotype | 1 | 2021 | 16262 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7835 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13692 | 0.060 |
Why?
|
Aged | 6 | 2021 | 161379 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11303 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18337 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7022 | 0.050 |
Why?
|
United States | 2 | 2022 | 68433 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 173 | 0.050 |
Why?
|
Role | 1 | 2020 | 179 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12937 | 0.050 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 288 | 0.040 |
Why?
|
Middle Aged | 5 | 2021 | 212155 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 550 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8577 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 51853 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 357 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4446 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 687 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1246 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 1057 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2023 | 1250 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 39883 | 0.040 |
Why?
|
Mutation | 1 | 2020 | 29645 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 692 | 0.030 |
Why?
|
Androgens | 1 | 2023 | 1248 | 0.030 |
Why?
|
Perception | 1 | 2021 | 1171 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23445 | 0.030 |
Why?
|
Female | 3 | 2017 | 375303 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2727 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1679 | 0.030 |
Why?
|
Animals | 3 | 2023 | 168735 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1544 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2020 | 2352 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2022 | 61674 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6457 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2618 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 6881 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2020 | 1738 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4196 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8492 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5562 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11486 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16634 | 0.010 |
Why?
|
Adult | 1 | 2015 | 211523 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 38720 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 19903 | 0.010 |
Why?
|
Mice | 1 | 2023 | 80318 | 0.010 |
Why?
|